SCHEMBL1970024

SCHEMBL1970024

CCc1cc2c(N3CCn4c(nnc4C(F)(F)F)C3)nc(Cl)nc2s1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 5/20 0.62
HTR6 P50406 1/20 0.44
MEN1 O00255 7/20 0.43
KMT2A Q03164 6/20 0.43
SMN1; SMN2 Q16637 4/20 0.39
KDM4E B2RXH2 2/20 0.39
TMIGD3 P0DMS9 1/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HRH4 Q9H3N8 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 3/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967936 0.92 P2RY12 (0.72) P2RY12HTR6MEN1KMT2ANOTUM
SCHEMBL1969602 0.92 P2RY12 (0.53) P2RY12HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL12409406 0.91 P2RY12 (0.65) P2RY12HTR6MEN1KMT2ANOTUM
SCHEMBL1973330 0.90 P2RY12 (0.57) P2RY12HTR6MEN1KMT2ANOTUM
SCHEMBL1972637 0.89 P2RY12 (0.60) P2RY12HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL1970100 0.89 P2RY12 (0.62) P2RY12HTR6MEN1KMT2ANOTUM
SCHEMBL1972124 0.87 P2RY12 (0.53) P2RY12NOTUM
SCHEMBL1968984 0.87 P2RY12 (0.60) P2RY12HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL12409612 0.86 HTR6 (0.50) P2RY12HTR6MEN1KMT2ASMN1; SMN2
SCHEMBL3377109 0.86 P2RY12 (0.59) P2RY12HTR6MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 P2RY12 127/4885HTR6 3031/4885MEN1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.